@FierceMedDev: Intelesens gets FDA approval for its Zensor wearable vital signs device. More | Follow @FierceMedDev
@VarunSaxena2: California cutbacks: BD cuts 95 at CareFusion; Medtronic to cut 21 at distribution facility. Report | Follow @VarunSaxena2
@EmilyWFierce: Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C. FiercePharma report | Follow @EmilyWFierce
> The FDA released a draft guidance about general considerations for animal studies of medical devices. More
> A third patient implanted with Carmat's investigational permanent artificial heart is faring well 6 months after receiving the device, reassuring news after the first two patients 74 days and then 9 months post-implantation. More
Biotech News
@FierceBiotech: Zafgen finally breaks its silence, says it's probing death of a patient. Report | Follow @FierceBiotech
@JohnCFierce: Still trending -- Moderna's top scientist steps down amid a billion-dollar R&D push by @DamianFierce. Article | Follow @JohnCFierce
@DamianFierce: There is perhaps no greater tribute to Steve Jobs than obfuscating your business model and threatening your critics. WSJ story | Follow @DamianFierce
> Bristol-Myers inks a blockbuster $1.74B deal for an Opdivo combo drug. Story
> Galapagos moves third component of AbbVie-partnered CF therapy toward clinic. Report
> Hearing the call of a new quest, Third Rock answers with $52M biotech startup. Article
> FierceBiotech Radio on Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand. More | Subscribe
Pharma News
@FiercePharma: ICYMI: Can J&J's Invokana reap the benefits of Lilly and BI's new cardiac data? Its CFO thinks so. Article | Follow @FiercePharma
@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. FiercePharmaManufacturing article | Follow @EricPFierce
@CarlyHFierce: UPDATED: Mylan hopes new show-and-tell will woo Perrigo shareholders. Story | Follow @CarlyHFierce
> Valeant hit with two federal subpoenas as drug-price controversy rages on. Story
> Pfizer CEO: Drug-pricing snafu isn't pharma's fault. It's insurers and their poor coverage. More
> Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C. Article
CRO News
> INC bolsters its Phase I platform with new cardiac tech. Story
> Aesica bids to manage its clients' many contractors. More
> Cel-Sci lines up cash to fund its $50M suit against ex-partner inVentiv. Report
> CRO Frontage gets into agrochemicals with new service offering. Story
> PRA adds a biotech vet to its board amid an expansion effort. Article
Pharma Manufacturing News
> Myanmar offers incentives to lure its drug distributors into production. News
> Medline recalls 500 mg acetaminophen labeled as 325 mg. More
> Valeant's Bausch + Lomb plant getting $150M in investments, up to 200 jobs. Report
> Chinese company intends to build plant to produce Ebola vax. Article
> GSK selling its drug distribution biz in Romania. Story
Pharma Asia News
> Superbug infections drop in China with new controls on antibiotics. Article
> China's State Council urges Suzhou Industrial Park to be more innovative. Story
> Japanese drug regulator opening Indian office. Item
> Lupin inks deal with Boehringer for diabetes drugs in India. News